Controlling CAR T cell therapy with small molecules for better cancer treatment
Precision Control of Universal CAR Activity by Small Molecule Adaptors
['FUNDING_R01'] · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · NIH-11050055
This study is testing a new type of CAR T cell therapy called SNAP-CAR, which aims to make treatment for blood cancers more effective and flexible by using special molecules that help the therapy target different cancer cells better, so patients can have a more personalized and powerful option for their treatment.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PITTSBURGH AT PITTSBURGH (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-11050055 on ClinicalTrials.gov |
What this research studies
This research focuses on improving CAR T cell therapy, a groundbreaking treatment for blood cancers, by developing a universal CAR called SNAP-CAR that can be programmed to target various cancer cells. The approach involves using small molecule adaptors that can enhance the specificity and effectiveness of these CAR T cells, making them more adaptable to different types of tumors and potentially autoimmune diseases. By utilizing these small molecules, the research aims to overcome current challenges in CAR T therapy, such as limited targeting ability and complex manufacturing processes. Patients may benefit from a more effective and versatile treatment option that can be tailored to their specific cancer type.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with blood cancers, solid tumors, or autoimmune diseases who may benefit from advanced CAR T cell therapies.
Not a fit: Patients with conditions unrelated to cancer or autoimmune diseases may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer therapies for patients.
How similar studies have performed: Other research has shown promise in enhancing CAR T cell therapies, but this approach using small molecule adaptors is relatively novel.
Where this research is happening
PITTSBURGH, UNITED STATES
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DEITERS, ALEXANDER — UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- Study coordinator: DEITERS, ALEXANDER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, Autoimmune Diseases, autoimmune disorder